Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
85.00-3.84 (-4.32%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close88.84
Bid84.81 x 100
Ask86.62 x 100
Day's Range84.99 - 90.77
52wk Range75.90 - 134.71
1y Target EstN/A
Market Cap21.06B
P/E Ratio (ttm)-74.96
Avg Vol (3m)1,336,589
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure
    Investor's Business Daily8 hours ago

    Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure

    A California ballot initiative requiring the state's Medicaid arm to buy drugs at comparable prices to what the VA pays could backfire, RBC says.

  • American City Business Journals18 hours ago

    ​Vertex confirms fears that latest drug launch is slower than hoped

    On Wednesday evening, Vertex Pharmaceuticals lowered full-year revenue predictions for its newest cystic fibrosis drug, effectively confirming fears investors first had a couple of weeks ago following comments by Vertex executives at a conference. While announcing the news that the U.S. Food and Drug Administration has approved Orkambi for use in patients ages 6-11 (it was previously able to be used in patients 12 and up), Vertex (VRTX) officials said the company now expects sales of the drug in 2016 to come in between $950 million and $990 million.

  • Reutersyesterday

    FDA approves expanded use of Vertex Pharma's cystic fibrosis drug

    Vertex Pharamceuticals Inc said the U.S. Food and Drug Administration expanded the use of its cystic fibrosis drug to treat a new subgroup of patients with the rare genetic disorder. The FDA approved the use of Orkambi in children with cystic fibrosis aged 6-11 who have a type of the mutation. Cystic fibrosis is a life-threatening condition, where a defective gene disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections.